MX2022010440A - 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi- 5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparacion y uso. - Google Patents

2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi- 5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparacion y uso.

Info

Publication number
MX2022010440A
MX2022010440A MX2022010440A MX2022010440A MX2022010440A MX 2022010440 A MX2022010440 A MX 2022010440A MX 2022010440 A MX2022010440 A MX 2022010440A MX 2022010440 A MX2022010440 A MX 2022010440A MX 2022010440 A MX2022010440 A MX 2022010440A
Authority
MX
Mexico
Prior art keywords
quinazolin
piperazin
methoxyphenyl
trifluoromethyl
fluoro
Prior art date
Application number
MX2022010440A
Other languages
English (en)
Inventor
Helmut Buschmann
Thomas Goldner
Bertran Jordi Carles Ceron
Original Assignee
Aic246 Ag & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag & Co Kg filed Critical Aic246 Ag & Co Kg
Publication of MX2022010440A publication Critical patent/MX2022010440A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la nueva 3,4-dihidroquinazolina , 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi -5-(trifluorometil)fenil]-4H-quinazolin-4-il] acetato de sodio monohidrato, métodos para su preparación, así como composiciones farmacéuticas que contienen dicha 3,4-dihidroquinazolina. Dicho compuesto es particularmente útil para el tratamiento y prevención de enfermedades asociadas con citomegalovirus (CMV), particularmente citomegalovirus humano (HCMV).
MX2022010440A 2020-02-27 2021-03-01 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi- 5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparacion y uso. MX2022010440A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159709 2020-02-27
PCT/EP2021/055065 WO2021170879A1 (en) 2020-02-27 2021-03-01 Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate monohydrate, its preparation and use

Publications (1)

Publication Number Publication Date
MX2022010440A true MX2022010440A (es) 2022-10-18

Family

ID=69742712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010440A MX2022010440A (es) 2020-02-27 2021-03-01 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi- 5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparacion y uso.

Country Status (21)

Country Link
US (1) US20230219900A1 (es)
EP (1) EP4110469A1 (es)
JP (1) JP7579350B2 (es)
KR (1) KR20220147655A (es)
CN (1) CN115427111A (es)
AR (1) AR121440A1 (es)
AU (1) AU2021225364B2 (es)
BR (1) BR112022016906A2 (es)
CA (1) CA3169473A1 (es)
CL (1) CL2022002290A1 (es)
CO (1) CO2022012017A2 (es)
CU (1) CU20220047A7 (es)
EC (1) ECSP22066670A (es)
IL (1) IL295633A (es)
MX (1) MX2022010440A (es)
MY (1) MY210486A (es)
PE (1) PE20230347A1 (es)
PY (1) PY2116987A (es)
TW (1) TWI886221B (es)
UY (1) UY39098A (es)
WO (1) WO2021170879A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119731157A (zh) * 2022-08-15 2025-03-28 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
PY24113872A (es) 2023-12-21 2025-07-29 Aic 246 Ag & Co Kg Sales diastereoméricas de aminoalchohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica.-

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
TW202140454A (zh) 2021-11-01
CL2022002290A1 (es) 2023-02-03
CU20220047A7 (es) 2023-04-10
TWI886221B (zh) 2025-06-11
PY2116987A (es) 2021-12-01
JP7579350B2 (ja) 2024-11-07
KR20220147655A (ko) 2022-11-03
US20230219900A1 (en) 2023-07-13
JP2023519809A (ja) 2023-05-15
AU2021225364A1 (en) 2022-10-13
CN115427111A (zh) 2022-12-02
CO2022012017A2 (es) 2022-11-18
AR121440A1 (es) 2022-06-08
UY39098A (es) 2021-09-30
ECSP22066670A (es) 2022-12-30
AU2021225364B2 (en) 2024-11-28
WO2021170879A1 (en) 2021-09-02
BR112022016906A2 (pt) 2022-12-06
IL295633A (en) 2022-10-01
NZ792571A (en) 2025-07-25
PE20230347A1 (es) 2023-03-02
EP4110469A1 (en) 2023-01-04
CA3169473A1 (en) 2021-09-02
MY210486A (en) 2025-09-25

Similar Documents

Publication Publication Date Title
CL2022002290A1 (es) Acetato de sodio monohidrato, su preparación y uso
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
PE20050965A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
PE20140966A1 (es) Quinazolincarboxamida azetidinas
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
NZ607580A (en) N-heteroaryl compounds
PH12021552004A1 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
IN2012DN02502A (es)
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
MX2024002696A (es) Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central.
PH12019500597A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP2886112A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF EYE DISEASES WITH S-ALLYL-L-CYSTEIN AS AN ACTIVE AND PHARMACEUTICAL FORMULATION THEREWITH
MX2014014066A (es) Compuestos de cromano.
ECSP22066666A (es) Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
GEAP202416566A (en) Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl) piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions
CU20220049A7 (es) Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden
BRPI0510451A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização
BR112014026776A2 (pt) derivados de pirimidina para o tratamento de doenças bacterianas
PL447202A1 (pl) Związek będący inhibitorem oddziaływania PD-L1/PD-1, kompozycja farmaceutyczna zawierająca inhibitor, oraz zastosowanie inhibitora